Digital Breast Tomosynthesis Market by Component (Hardware, Services, Software), End User (Academic And Research Institutes, Breast Cancer Clinics, Diagnostic Imaging Centers), Application, Technology, Installation - Global Forecast 2025-2032
Description
The Digital Breast Tomosynthesis Market was valued at USD 4.41 billion in 2024 and is projected to grow to USD 5.09 billion in 2025, with a CAGR of 15.28%, reaching USD 13.77 billion by 2032.
A concise introductory framing of digital breast tomosynthesis evolution, clinical adoption drivers, and the operational implications for healthcare delivery and imaging leaders
Digital breast tomosynthesis has matured from a niche, investigational imaging technique into a mainstream diagnostic modality that is reshaping breast imaging workflows across diverse care settings. Over the past decade, improvements in detector technology, reconstruction algorithms, and dose-optimization strategies have driven wider clinical acceptance. As clinicians pursue greater lesion conspicuity and reduced recall rates compared with traditional two-dimensional mammography, tomosynthesis has become integral to diagnostic and screening pathways in many advanced care systems.
Consequently, healthcare administrators and imaging leaders are reconsidering capital allocation, clinical protocols, and workforce training to integrate tomosynthesis into routine practice. This shift is informed by multi-disciplinary collaboration among radiologists, physicists, and technologists, who emphasize standardized acquisition protocols and quality assurance. Moreover, the interplay between hardware advances and software-enabled image processing has introduced new possibilities for AI-driven triage, lesion characterization, and workflow automation. Transitional investments now focus not only on equipment procurement but also on sustaining clinical adoption through education, service agreements, and interoperable IT infrastructure. In this context, stakeholders must balance clinical benefit, operational feasibility, and the evolving regulatory landscape to design effective implementation roadmaps.
An overview of the converging technological, regulatory, and clinical forces that are reshaping diagnostic imaging workflows and accelerating strategic shifts in breast tomosynthesis adoption
The landscape of breast imaging is undergoing transformative shifts driven by converging technological, regulatory, and clinical dynamics. On the technological front, the integration of enhanced detector sensitivity, multi-slice acquisition modes, and advanced reconstruction techniques is improving lesion visualization while maintaining acceptable radiation dose profiles. Parallel advances in AI and machine learning are enabling more robust image interpretation support, automated triage workflows, and volumetric analytics, which collectively reduce reading time and augment diagnostic confidence.
Regulatory frameworks are adapting to accommodate software as a medical device and to define pathways for validation of AI-enabled decision support, thereby influencing procurement and deployment timelines. Clinically, the emphasis on personalized screening and risk-based protocols is prompting healthcare systems to integrate tomosynthesis selectively for populations where its diagnostic yield is maximized. Operationally, vendors and providers are rethinking service models to include subscription-based software updates, remote diagnostics, and outcome-linked service-level agreements. Together, these shifts are creating a more software-centric, data-driven ecosystem in which interoperable platforms and evidence-backed clinical value propositions determine adoption momentum.
A strategic assessment of how evolving tariff regimes and trade policy dynamics influence procurement decisions, supply chain resilience, and the total cost of ownership for imaging assets
Trade policy developments, including tariffs and import duties, have tangible implications for procurement strategies, supply chain resilience, and total cost of ownership for imaging equipment. Tariff adjustments in major markets can alter pricing dynamics for manufacturers and distributors, prompting re-evaluation of sourcing, regional manufacturing footprints, and vendor selection criteria. In response, global suppliers may accelerate localization of production, expand regional service hubs, and renegotiate supplier contracts to mitigate tariff exposure.
For healthcare providers, these macroeconomic headwinds highlight the importance of multi-year procurement planning, long-term service agreements, and lifecycle cost analysis that incorporates potential policy-driven price volatility. Decision-makers are increasingly prioritizing vendors with diversified supply chains, established regional support networks, and transparent cost structures. Meanwhile, clinical leaders must remain cognizant of how procurement delays or cost increases could affect rollout schedules, training programs, and maintenance budgets. Overall, the cumulative effect of tariff shifts is to elevate strategic risk assessment in capital planning and to incentivize partnerships that can provide predictable access to equipment, software updates, and technical support despite cross-border trade uncertainties.
Insightful segmentation analysis connecting hardware, services, and software with clinical settings, application needs, technology configurations, and installation modalities to reveal adoption drivers
A granular understanding of market segmentation reveals where investment, clinical value, and operational complexity converge. When examined by component, the ecosystem comprises hardware, services, and software, each contributing distinct value streams: hardware investments determine acquisition and physical capacity, services sustain uptime and clinical productivity, and software drives image reconstruction, analytics, and workflow integration. By end user, adoption patterns differ across academic and research institutes, breast cancer clinics, diagnostic imaging centers, and hospitals, with each setting imposing unique clinical workflow requirements and procurement priorities.
Application-wise, diagnostic and screening use cases necessitate differing throughput, sensitivity, and reporting capabilities, shaping system selection and clinical protocols. Technology segmentation between integrated tomosynthesis systems and standalone units influences deployment choices, interoperability considerations, and upgrade pathways, while installation mode-fixed units versus mobile units-affects reach, patient access strategies, and logistical planning for outreach programs. Synthesizing these segments clarifies where clinical need aligns with commercial opportunity, where service models must be tailored to context, and where partnerships between vendors and providers can accelerate adoption while managing operational risk.
A regional analysis of market characteristics and clinical priorities across the Americas, Europe, Middle East & Africa, and Asia-Pacific that influence adoption pathways and deployment strategies
Regional dynamics shape the competitive environment for tomosynthesis deployment, with distinctive clinical priorities, reimbursement models, and infrastructure maturity across geographies. In the Americas, healthcare systems are focused on balancing innovation with cost containment, leading to targeted adoption in centers of excellence and progressive screening programs, while private imaging networks prioritize throughput and value-based partnerships. In Europe, Middle East & Africa, heterogeneous regulatory regimes and variable access to capital create a mosaic of adoption pathways where public health priorities, national screening guidelines, and regional manufacturing capabilities influence procurement decisions.
In the Asia-Pacific region, rapid modernization of healthcare infrastructure, expanding private care networks, and growing public health initiatives are increasing demand for advanced imaging, though deployment strategies vary from urban tertiary hospitals to mobile screening initiatives in underserved areas. Across all regions, interoperability with electronic health records, local clinical guidelines, and availability of trained personnel remain critical determinants of successful implementation. Consequently, vendors and health systems must tailor product offerings, training programs, and service models to regional nuances to ensure sustained clinical value and operational viability.
An examination of competitive strategies and company behaviors that combine hardware innovation, expanded service offerings, and software partnerships to capture clinical adoption and market presence
Competitive dynamics in the tomosynthesis domain are shaped by firms that combine robust hardware engineering with scalable service networks and evolving software capabilities. Leading companies are differentiating through investments in image quality, reconstruction speed, and dose optimization, as well as through extended service offerings that include remote diagnostics, predictive maintenance, and outcome-oriented support. These market participants are also forging partnerships with AI developers, academic centers, and clinical consortia to validate performance and accelerate clinician acceptance.
Smaller and niche vendors are competing on flexibility, cost-effective upgrade paths for legacy systems, and specialized clinical workflows tailored to breast clinics and screening programs. Channel partners and distributors play a pivotal role in regions with complex regulatory environments or fragmented purchasing ecosystems. Strategic alliances, OEM relationships, and flexible commercial models-such as managed services and software subscriptions-are becoming common tactics to deepen market penetration and to align vendor incentives with clinical outcomes. Collectively, these approaches are reshaping how companies compete and collaborate within the broader diagnostic imaging value chain.
Actionable strategic recommendations for industry leaders focused on clinical impact, operational resilience, software integration, supply chain diversification, and evidence generation
Industry leaders must adopt a multi-dimensional strategy that addresses clinical efficacy, operational resilience, and commercial flexibility. First, prioritize investments in systems that demonstrably improve diagnostic workflows while minimizing radiation dose, and pair those systems with comprehensive training and standardized acquisition protocols to ensure consistent clinical outcomes. Second, develop service models that reduce downtime risk through preventive maintenance, remote monitoring, and regional support hubs to sustain productivity and clinical confidence.
Third, accelerate software-enabled value by integrating advanced reconstruction algorithms, AI-assisted triage, and interoperable reporting tools that streamline radiologist workflows and facilitate multidisciplinary care coordination. Fourth, mitigate procurement risk by diversifying supply chain partners, exploring localized manufacturing or assembly options, and adopting flexible commercial terms such as phased rollouts or managed service contracts. Finally, invest in real-world evidence generation and collaborative validation studies with clinical partners to substantiate clinical benefits and to support payer engagement. Implementing these recommendations will position organizations to capture clinical value while managing financial and operational risk effectively.
A transparent outline of the mixed-methods research approach combining primary interviews, secondary literature review, and rigorous analytical validation to ensure clinical and technical accuracy
This analysis synthesizes primary and secondary research to deliver a balanced perspective on clinical, technological, and commercial factors shaping tomosynthesis adoption. Primary inputs include structured interviews with radiologists, imaging directors, clinical technologists, and procurement leaders, complemented by expert consultations with clinical trial investigators and imaging physicists. Secondary sources encompass peer-reviewed literature, public regulatory documents, clinical guidelines, and manufacturer technical briefs to triangulate technology performance, clinical utility, and regulatory trajectories.
Analytical methods include thematic coding of qualitative interviews to identify adoption barriers and enablers, comparative assessment of system features to map capability differentials, and scenario analysis to understand operational implications under varying procurement and service models. Quality assurance steps include cross-validation of factual claims against multiple independent sources and peer review by clinical advisers to ensure clinical accuracy. Throughout, stakeholder confidentiality and ethical research practices were upheld to ensure candid insights while preserving proprietary perspectives.
A conclusive synthesis that connects technological promise with the operational and strategic imperatives necessary to achieve sustained clinical and organizational impact
Digital breast tomosynthesis represents a pivotal advancement in breast imaging that intersects clinical benefit with operational complexity and commercial innovation. Its adoption is being shaped by continual improvements in image acquisition, reconstruction, and software-enabled analytics, alongside changing regulatory frameworks and procurement realities. Stakeholders must therefore adopt integrated strategies that account for clinical workflow redesign, workforce competency, service reliability, and adaptable commercial terms to realize the modality's full potential.
Looking ahead, successful organizations will be those that align technology selection with clearly defined clinical objectives, invest in interoperable software and training, and construct procurement plans that mitigate supply chain and policy risks. Collaboration across vendors, clinicians, and health system leaders will be essential to translate technological capability into measurable improvements in diagnostic pathways and patient outcomes. In sum, tomosynthesis offers significant clinical promise, and its strategic deployment requires disciplined planning, evidence-based validation, and operational foresight to achieve sustainable impact.
Please Note: PDF & Excel + Online Access - 1 Year
A concise introductory framing of digital breast tomosynthesis evolution, clinical adoption drivers, and the operational implications for healthcare delivery and imaging leaders
Digital breast tomosynthesis has matured from a niche, investigational imaging technique into a mainstream diagnostic modality that is reshaping breast imaging workflows across diverse care settings. Over the past decade, improvements in detector technology, reconstruction algorithms, and dose-optimization strategies have driven wider clinical acceptance. As clinicians pursue greater lesion conspicuity and reduced recall rates compared with traditional two-dimensional mammography, tomosynthesis has become integral to diagnostic and screening pathways in many advanced care systems.
Consequently, healthcare administrators and imaging leaders are reconsidering capital allocation, clinical protocols, and workforce training to integrate tomosynthesis into routine practice. This shift is informed by multi-disciplinary collaboration among radiologists, physicists, and technologists, who emphasize standardized acquisition protocols and quality assurance. Moreover, the interplay between hardware advances and software-enabled image processing has introduced new possibilities for AI-driven triage, lesion characterization, and workflow automation. Transitional investments now focus not only on equipment procurement but also on sustaining clinical adoption through education, service agreements, and interoperable IT infrastructure. In this context, stakeholders must balance clinical benefit, operational feasibility, and the evolving regulatory landscape to design effective implementation roadmaps.
An overview of the converging technological, regulatory, and clinical forces that are reshaping diagnostic imaging workflows and accelerating strategic shifts in breast tomosynthesis adoption
The landscape of breast imaging is undergoing transformative shifts driven by converging technological, regulatory, and clinical dynamics. On the technological front, the integration of enhanced detector sensitivity, multi-slice acquisition modes, and advanced reconstruction techniques is improving lesion visualization while maintaining acceptable radiation dose profiles. Parallel advances in AI and machine learning are enabling more robust image interpretation support, automated triage workflows, and volumetric analytics, which collectively reduce reading time and augment diagnostic confidence.
Regulatory frameworks are adapting to accommodate software as a medical device and to define pathways for validation of AI-enabled decision support, thereby influencing procurement and deployment timelines. Clinically, the emphasis on personalized screening and risk-based protocols is prompting healthcare systems to integrate tomosynthesis selectively for populations where its diagnostic yield is maximized. Operationally, vendors and providers are rethinking service models to include subscription-based software updates, remote diagnostics, and outcome-linked service-level agreements. Together, these shifts are creating a more software-centric, data-driven ecosystem in which interoperable platforms and evidence-backed clinical value propositions determine adoption momentum.
A strategic assessment of how evolving tariff regimes and trade policy dynamics influence procurement decisions, supply chain resilience, and the total cost of ownership for imaging assets
Trade policy developments, including tariffs and import duties, have tangible implications for procurement strategies, supply chain resilience, and total cost of ownership for imaging equipment. Tariff adjustments in major markets can alter pricing dynamics for manufacturers and distributors, prompting re-evaluation of sourcing, regional manufacturing footprints, and vendor selection criteria. In response, global suppliers may accelerate localization of production, expand regional service hubs, and renegotiate supplier contracts to mitigate tariff exposure.
For healthcare providers, these macroeconomic headwinds highlight the importance of multi-year procurement planning, long-term service agreements, and lifecycle cost analysis that incorporates potential policy-driven price volatility. Decision-makers are increasingly prioritizing vendors with diversified supply chains, established regional support networks, and transparent cost structures. Meanwhile, clinical leaders must remain cognizant of how procurement delays or cost increases could affect rollout schedules, training programs, and maintenance budgets. Overall, the cumulative effect of tariff shifts is to elevate strategic risk assessment in capital planning and to incentivize partnerships that can provide predictable access to equipment, software updates, and technical support despite cross-border trade uncertainties.
Insightful segmentation analysis connecting hardware, services, and software with clinical settings, application needs, technology configurations, and installation modalities to reveal adoption drivers
A granular understanding of market segmentation reveals where investment, clinical value, and operational complexity converge. When examined by component, the ecosystem comprises hardware, services, and software, each contributing distinct value streams: hardware investments determine acquisition and physical capacity, services sustain uptime and clinical productivity, and software drives image reconstruction, analytics, and workflow integration. By end user, adoption patterns differ across academic and research institutes, breast cancer clinics, diagnostic imaging centers, and hospitals, with each setting imposing unique clinical workflow requirements and procurement priorities.
Application-wise, diagnostic and screening use cases necessitate differing throughput, sensitivity, and reporting capabilities, shaping system selection and clinical protocols. Technology segmentation between integrated tomosynthesis systems and standalone units influences deployment choices, interoperability considerations, and upgrade pathways, while installation mode-fixed units versus mobile units-affects reach, patient access strategies, and logistical planning for outreach programs. Synthesizing these segments clarifies where clinical need aligns with commercial opportunity, where service models must be tailored to context, and where partnerships between vendors and providers can accelerate adoption while managing operational risk.
A regional analysis of market characteristics and clinical priorities across the Americas, Europe, Middle East & Africa, and Asia-Pacific that influence adoption pathways and deployment strategies
Regional dynamics shape the competitive environment for tomosynthesis deployment, with distinctive clinical priorities, reimbursement models, and infrastructure maturity across geographies. In the Americas, healthcare systems are focused on balancing innovation with cost containment, leading to targeted adoption in centers of excellence and progressive screening programs, while private imaging networks prioritize throughput and value-based partnerships. In Europe, Middle East & Africa, heterogeneous regulatory regimes and variable access to capital create a mosaic of adoption pathways where public health priorities, national screening guidelines, and regional manufacturing capabilities influence procurement decisions.
In the Asia-Pacific region, rapid modernization of healthcare infrastructure, expanding private care networks, and growing public health initiatives are increasing demand for advanced imaging, though deployment strategies vary from urban tertiary hospitals to mobile screening initiatives in underserved areas. Across all regions, interoperability with electronic health records, local clinical guidelines, and availability of trained personnel remain critical determinants of successful implementation. Consequently, vendors and health systems must tailor product offerings, training programs, and service models to regional nuances to ensure sustained clinical value and operational viability.
An examination of competitive strategies and company behaviors that combine hardware innovation, expanded service offerings, and software partnerships to capture clinical adoption and market presence
Competitive dynamics in the tomosynthesis domain are shaped by firms that combine robust hardware engineering with scalable service networks and evolving software capabilities. Leading companies are differentiating through investments in image quality, reconstruction speed, and dose optimization, as well as through extended service offerings that include remote diagnostics, predictive maintenance, and outcome-oriented support. These market participants are also forging partnerships with AI developers, academic centers, and clinical consortia to validate performance and accelerate clinician acceptance.
Smaller and niche vendors are competing on flexibility, cost-effective upgrade paths for legacy systems, and specialized clinical workflows tailored to breast clinics and screening programs. Channel partners and distributors play a pivotal role in regions with complex regulatory environments or fragmented purchasing ecosystems. Strategic alliances, OEM relationships, and flexible commercial models-such as managed services and software subscriptions-are becoming common tactics to deepen market penetration and to align vendor incentives with clinical outcomes. Collectively, these approaches are reshaping how companies compete and collaborate within the broader diagnostic imaging value chain.
Actionable strategic recommendations for industry leaders focused on clinical impact, operational resilience, software integration, supply chain diversification, and evidence generation
Industry leaders must adopt a multi-dimensional strategy that addresses clinical efficacy, operational resilience, and commercial flexibility. First, prioritize investments in systems that demonstrably improve diagnostic workflows while minimizing radiation dose, and pair those systems with comprehensive training and standardized acquisition protocols to ensure consistent clinical outcomes. Second, develop service models that reduce downtime risk through preventive maintenance, remote monitoring, and regional support hubs to sustain productivity and clinical confidence.
Third, accelerate software-enabled value by integrating advanced reconstruction algorithms, AI-assisted triage, and interoperable reporting tools that streamline radiologist workflows and facilitate multidisciplinary care coordination. Fourth, mitigate procurement risk by diversifying supply chain partners, exploring localized manufacturing or assembly options, and adopting flexible commercial terms such as phased rollouts or managed service contracts. Finally, invest in real-world evidence generation and collaborative validation studies with clinical partners to substantiate clinical benefits and to support payer engagement. Implementing these recommendations will position organizations to capture clinical value while managing financial and operational risk effectively.
A transparent outline of the mixed-methods research approach combining primary interviews, secondary literature review, and rigorous analytical validation to ensure clinical and technical accuracy
This analysis synthesizes primary and secondary research to deliver a balanced perspective on clinical, technological, and commercial factors shaping tomosynthesis adoption. Primary inputs include structured interviews with radiologists, imaging directors, clinical technologists, and procurement leaders, complemented by expert consultations with clinical trial investigators and imaging physicists. Secondary sources encompass peer-reviewed literature, public regulatory documents, clinical guidelines, and manufacturer technical briefs to triangulate technology performance, clinical utility, and regulatory trajectories.
Analytical methods include thematic coding of qualitative interviews to identify adoption barriers and enablers, comparative assessment of system features to map capability differentials, and scenario analysis to understand operational implications under varying procurement and service models. Quality assurance steps include cross-validation of factual claims against multiple independent sources and peer review by clinical advisers to ensure clinical accuracy. Throughout, stakeholder confidentiality and ethical research practices were upheld to ensure candid insights while preserving proprietary perspectives.
A conclusive synthesis that connects technological promise with the operational and strategic imperatives necessary to achieve sustained clinical and organizational impact
Digital breast tomosynthesis represents a pivotal advancement in breast imaging that intersects clinical benefit with operational complexity and commercial innovation. Its adoption is being shaped by continual improvements in image acquisition, reconstruction, and software-enabled analytics, alongside changing regulatory frameworks and procurement realities. Stakeholders must therefore adopt integrated strategies that account for clinical workflow redesign, workforce competency, service reliability, and adaptable commercial terms to realize the modality's full potential.
Looking ahead, successful organizations will be those that align technology selection with clearly defined clinical objectives, invest in interoperable software and training, and construct procurement plans that mitigate supply chain and policy risks. Collaboration across vendors, clinicians, and health system leaders will be essential to translate technological capability into measurable improvements in diagnostic pathways and patient outcomes. In sum, tomosynthesis offers significant clinical promise, and its strategic deployment requires disciplined planning, evidence-based validation, and operational foresight to achieve sustainable impact.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
186 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of artificial intelligence algorithms in digital breast tomosynthesis for improved lesion detection and workflow efficiency
- 5.2. Development of portable and low-dose digital breast tomosynthesis systems to expand screening access in remote and underserved regions
- 5.3. Adoption of contrast-enhanced digital breast tomosynthesis techniques for enhanced visualization of tumor vascularity and lesion characterization
- 5.4. Implementation of automated quality control and dose optimization software in digital breast tomosynthesis to reduce radiation exposure for patients
- 5.5. Expansion of personalized breast imaging protocols based on patient-specific breast density and risk assessment in tomosynthesis screening programs
- 5.6. Collaboration between imaging device manufacturers and cloud-based analytics platforms for centralized storage and AI-driven interpretation of tomosynthesis data
- 5.7. Growth of reimbursement policies favoring digital breast tomosynthesis as a first-line screening modality supported by emerging clinical outcome studies
- 5.8. Development of combined digital breast tomosynthesis and synthetic two-dimensional mammography modalities to streamline diagnostic workflows and reduce examination times
- 5.9. Integration of 3D printing with digital breast tomosynthesis data for pre-surgical planning and creation of patient-specific breast phantoms
- 5.10. Emergence of telemammography services leveraging digital breast tomosynthesis for remote consultation and second-opinion diagnostics
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Digital Breast Tomosynthesis Market, by Component
- 8.1. Hardware
- 8.2. Services
- 8.3. Software
- 9. Digital Breast Tomosynthesis Market, by End User
- 9.1. Academic And Research Institutes
- 9.2. Breast Cancer Clinics
- 9.3. Diagnostic Imaging Centers
- 9.4. Hospitals
- 10. Digital Breast Tomosynthesis Market, by Application
- 10.1. Diagnostic
- 10.2. Screening
- 11. Digital Breast Tomosynthesis Market, by Technology
- 11.1. Integrated Dbt
- 11.2. Standalone Dbt
- 12. Digital Breast Tomosynthesis Market, by Installation
- 12.1. Fixed Unit
- 12.2. Mobile Unit
- 13. Digital Breast Tomosynthesis Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Digital Breast Tomosynthesis Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Digital Breast Tomosynthesis Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. Hologic, Inc.
- 16.3.2. GE HealthCare Technologies Inc.
- 16.3.3. Siemens Healthineers AG
- 16.3.4. Fujifilm Holdings Corporation
- 16.3.5. Canon Medical Systems Corporation
- 16.3.6. Koninklijke Philips N.V.
- 16.3.7. Konica Minolta, Inc.
- 16.3.8. Carestream Health, Inc.
- 16.3.9. Shimadzu Corporation
- 16.3.10. Planmed Oy
- 16.3.11. Internazionale Medico Scientifica S.r.l.
- 16.3.12. Metaltronica S.p.A.
- 16.3.13. Villa Sistemi Medicali S.p.A.
- 16.3.14. Analogic Corporation
- 16.3.15. PerkinElmer, Inc.
- 16.3.16. Varex Imaging Corporation
- 16.3.17. Trivitron Healthcare Pvt. Ltd.
- 16.3.18. DMS Imaging Co., Ltd.
- 16.3.19. United Imaging Healthcare Co., Ltd.
- 16.3.20. IMS Giotto S.p.A.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
